Reported 1 day ago
Guggenheim has identified Compass Therapeutics Inc. (NASDAQ:CMPX) as a promising investment opportunity, driven by its lead program CTX-009, which is in clinical trials targeting biliary tract cancer. With a significant market potential estimated over $1 billion and a high unmet medical need for patients lacking effective treatments, analyst Michael Schmidt raised his price target on CMPX to $12 from $10 and maintained a Buy rating. Positive updates on their pipeline and trial progress suggest strengthening confidence in the company's future prospects.
Source: YAHOO